Zentalis Pharmaceuticals (ZNTL) Operating Expenses (2019 - 2026)

Zentalis Pharmaceuticals' Operating Expenses history runs 8 years deep, the most recent figure standing at $37.9 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 17.03% year-over-year to $37.9 million in Q1 2026; TTM through Mar 2026 was $145.0 million, a 39.29% decrease from a year earlier, with the FY2025 full-year figure at $152.8 million, down 40.91% from the prior year.
• Operating Expenses rose to $37.9 million in Q1 2026 per ZNTL's latest filing, from $37.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $103.9 million in Q2 2023 and bottomed at $33.7 million in Q3 2025.
• The 5-year median for Operating Expenses is $57.9 million (2022), against an average of $57.4 million.
• Across the five-year window, Operating Expenses soared 63.75% in 2023 and plunged 51.26% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $51.8 million in 2022, then jumped by 31.24% to $67.9 million in 2023, then grew by 12.94% to $76.7 million in 2024, then plunged by 51.26% to $37.4 million in 2025, then increased by 1.24% to $37.9 million in 2026.
• Per Business Quant, the three latest ZNTL Operating Expenses figures stand at $37.9 million (Q1 2026), $37.4 million (Q4 2025), and $33.7 million (Q3 2025).